Published on
May 22, 2024
- 15:20 GMT
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting Additional KT-621 preclinical data was also featured in a poster …
Distribution channels:
Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry
...
